Syllabus · Historical · V4 (2023) · Musculoskeletal System
L2 · Musculoskeletal System Pharmacology
L2.i · Musculoskeletal System Pharmacology
Understand the pharmacology of neuromuscular blocking drugs and reversal agents.
Written examination
SAQ history
Neuromuscular Blockade — Block Onset
3 exam appearances
In relation to neuromuscular blocking drugs – Discuss the factors that influence the speed of ONSET of neuromuscular block.
38%
Discuss the factors that may potentially influence the speed of onset of neuromuscular blockade.
16%
Neuromuscular Blockade — Block Potentiation
1 exam appearance
Outline the mechanisms that potentiate the action of non-depolarising muscle relaxants and give examples.
15%
Neuromuscular Blockade — Pharmacodynamic Variability
1 exam appearance
Outline three (3) factors that alter the pharmacodynamic response of non-depolarising neuro-muscular blocking drugs and describe the mechanism by which they may occur.
—
Rocuronium vs. Cisatracurium
1 exam appearance
Suxamethonium — Clinical Use
2 exam appearances
Outline the advantages (15% of marks) and disadvantages (85% of marks) of the clinical use of suxamethonium.
46%
Suxamethonium is a non-competitive partial agonist. Explain what is meant by this statement using definitions of the underlined terms (50% of marks). List the advantages and disadvantages of suxamethonium within Intensive Care practice (50% of marks).
59.1%
Suxamethonium — Pharmacology
3 exam appearances
Suxamethonium vs. Rocuronium
1 exam appearance
Vecuronium
2 exam appearances
Describe factors that prolong the action of neuromuscular blocking agents (60% of Marks) Outline the pharmacokinetics and pharmacodynamics of vecuronium (40% of Marks).
20%
Describe the pharmacology of vecuronium, including factors that prolong its action of neuromuscular blockade.
13%
Oral examination
VIVA history
-
2024A · Day 1 · VIVA 3
This VIVA will examine neuromuscular junction monitoring and neuromuscular blocking agents. Describe in detail the train of four (TOF)?
-
2019B · Day 3 · VIVA 1
This viva will test your knowledge of the pharmacology of neuromuscular blocking drugs, and local anaesthetics.
-
2018B · Day 2 · VIVA 8
This viva will initially explore the measurement of neuromuscular function and pharmacology of neuromuscular blocking drugs. What are the principles of a peripheral nerve stimulator? (Image removed from report.)
-
2018A · Day 2 · VIVA 3
This viva will examine nerve action potentials and neuromuscular blockade. Describe the graph shown below. (Image removed from report.)
-
2017B · Day 3 · VIVA 5
This viva is on neuromuscular physiology and the pharmacology of neuromuscular blockade. Describe the structure of the neuromuscular junction and the events that lead to an action potential in the muscle plasma membrane.
-
2017A · Day 2 · VIVA 7
This viva will test your knowledge of the neuromuscular junction and of assessment of neuromuscular blockade. Name the structures marked on the diagram at A, B, C and D. (Image removed.)
-
2016B · Day 1 · VIVA 1
This viva tested knowledge of neuromuscular blocking drug pharmacology and physiology of the deep tendon reflex.
-
2016B · Day 2 · VIVA 1
This viva tested knowledge of dose response curves and Neuromuscular blocking drug pharmacology
-
2016A · Day 2 · VIVA 5
This viva tested knowledge of electrophysiology and neuromuscular blocking drugs. It discussed ion concentrations across cell membranes, Action potentials, pharmacology of atracurium and assessing neuromuscular blockade.
-
2015B · VIVA 5
This Viva tested knowledge of the structure and function of the neuromuscular junction and the pharmacology of neuromuscular blocking drugs.
-
2015A · VIVA 4
This Viva tested knowledge on neuromuscular physiology and pharmacology. It explored the anatomy of a reflex arc, the physiology of neuromuscular transmission on and pharmacology of neuromuscular blocking drugs.
-
2011B · VIVA 4
The candidates were shown a diagram of a neuromuscular junction and asked to label the various components. Subsequent questions sought knowledge of the processes occurring at the prejunctional / junctional / post junctional nerve terminal, to classify neuromuscular blockers, their mechanisms of action, and the pharmacokinetic properties that influence speed of onset and potency.
-
2010A · VIVA 4
This station is concerned with the physiology and pharmacology related to the musculoskeletal system Candidates were asked to draw and label a sacromere, outline the physiological events relating to muscle contraction, length – tension relationship, muscle relaxants, malignant hyperthermia and dantrolene
-
2007B · VIVA 2
Brittle asthmatic requiring intubation; neuromuscular junction and neuromuscular blocking drug physiology/pharmacology.
Sources: objective text from the relevant CICM syllabus; historical SAQ and VIVA wording from CICM examiner reports.